China Microarray Market Size, Share, Forecast, & Trend Analysis by Product (Consumables [Microarray Kits {DNA (cDNA, Oligo), Protein}], Instruments, Software, Services), Application (Drug Discovery, Research, Diagnostics), End User— Forecast to 2031

October 2024 | 109 pages | ID: C9E471F2760AEN
Meticulous Market Research Pvt. Ltd.

US$ 4,175.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
China Microarray Market Size, Share, Forecast, & Trend Analysis by Product (Consumables [Microarray Kits {DNA (cDNA, Oligo), Protein}], Instruments, Software, Services), Application (Drug Discovery, Research, Diagnostics), End User—Forecast to 2031

The China microarray market is projected to reach $910.4 million by 2031, at a CAGR of 8.4% from 2024 to 2031.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by increasing research applications of the microarray technology, growth in genomics & proteomics research, rising prevalence of cancers & genetic disorders, and growing R&D expenditures in the pharmaceutical & biotechnology industries.

Additionally, advancements in microarray technology and the growing adoption of personalized medicines provide significant growth opportunities for this market. However, the elevated costs of microarray compared to other genetic testing methods may restrain the growth of this market. Furthermore, the lack of sensitivity and accuracy in microarray poses a major challenge for the players operating in this market.

Among the products studied in this report, in 2024, the consumables segment is expected to account for the largest share of the China microarray market. Consumables encompass kits and additional items necessary for microarray applications, ensuring comprehensive and optimal sample preparation for accurate results and analysis. The large market share is driven by factors including streamlined workflows, reduced errors, cost efficiency, and minimized waste.

Among the applications studied in this report, in 2024, the drug discovery & development segment is expected to account for the largest share of the China microarray market. This large market share is attributed to factors such as elevated pharmaceutical R&D expenditures, a growing demand for novel drugs, increased government funding for drug discovery and development, and the rising adoption of microarray technology for identifying suitable therapeutic targets.

Among the end users studied in this report, in 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the China microarray market. This large market share is driven by factors such as rising healthcare expenditures, increased investment and funding in pharmaceutical companies, advancements in research and development, and enhanced patient outcomes.

Some of the major players studied in this report are Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.).

Scope of the Report:

China Microarray Market Assessment—by Product

Consumables

Kits

DNA & RNA Microarray Kits

cDNA Microarray Kits

Oligo Microarray Kits

Other DNA & RNA Microarray Kits

(Other DNA & RNA microarray kits comprise RNA microarray, SNP microarray, and BAC microarray)

Protein Microarray Kits

Tissue Microarray Kits

Other Microarray Kits

(Other microarray kits comprise cell microarray, ChIP-chip microarray (Chromatin Immunoprecipitation Microarray), and glycan microarray)

Other Consumables

(Other consumables comprise buffers, reagents, slides, well plates, coated slides, and microtiter plates)

Instruments

Software

Services

China Microarray Market Assessment—by Application

Drug Discovery & Development

Research Applications

Diagnostics

Other Applications

(Other applications comprise agriculture, food & beverage, and forensics)

China Microarray Market Assessment—by End User

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Research & Academic Institutes

Hospitals & Diagnostic Laboratories

Other End Users

(Other end users comprise veterinary clinics, agricultural industry, and forensic laboratories)
1. INTRODUCTION

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Process
2.2. Process of Data Collection and Validation
  2.2.1. Secondary Research
  2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Size and Forecasting
  2.3.1. Market Size Estimation Approach
  2.3.2. Growth Forecast Approach
2.4. Assumptions for The Study

3. EXECUTIVE SUMMARY

4. MARKET INSIGHTS

4.1. Overview
4.2. Factors Affecting Market Growth
  4.2.1. Impact Analysis of Market Dynamics
  4.2.2. Macro Indicators
4.3. Key Trends
  4.3.1. Use of Microarrays in Forensics
  4.3.2. Growing Use of 3D-printed Microarrays
4.4. Regulatory Analysis
4.5. Pricing Analysis
4.6. PESTLE Analysis
  4.6.1. Political Factors
  4.6.2. Economic Factors
  4.6.3. Social Factors
  4.6.4. Technological Factors
  4.6.5. Legal Factors
  4.6.6. Environmental Factors
4.7. Parent/Adjacent Market Analysis
  4.7.1. IVD Industry Landscape

5. CHINA MICROARRAY MARKET ASSESSMENT—BY PRODUCT

5.1. Overview
5.2. Consumables
  5.2.1. Kits
    5.2.1.1. DNA & RNA Microarray Kits
      5.2.1.1.1. Oligo Microarray Kits
      5.2.1.1.2. cDNA Microarray Kits
      5.2.1.1.3. Other DNA & RNA Microarray Kits
    5.2.1.2. Protein Microarray Kits
    5.2.1.3. Tissue Microarray Kits
    5.2.1.4. Other Microarray Kits
  5.2.2. Other Consumables
5.3. Instruments
5.4. Software
5.5. Services

6. CHINA MICROARRAY MARKET—BY APPLICATION

6.1. Overview
6.2. Drug Discovery & Development
6.3. Diagnostics
6.4. Research Applications
6.5. Other Applications

7. CHINA MICROARRAY MARKET—BY END USER

7.1. Overview
7.2. Pharmaceutical and Biotechnology Companies
7.3. Contract Research Organizations (CROs)
7.4. Academic & Research Institutes
7.5. Hospitals & Diagnostic Laboratories
7.6. Other End Users

8. COMPETITION ANALYSIS

8.1. Overview
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Competitive Dashboard
  8.4.1. Industry Leaders
  8.4.2. Market Differentiators
  8.4.3. Vanguards
  8.4.4. Emerging Companies
8.5. Market Share Analysis (2023)
  8.5.1. Thermo Fisher Scientific Inc. (U.S.)
  8.5.2. Illumina, Inc. (U.S.)
  8.5.3. Merck KGaA (Germany)
  8.5.4. Revvity, Inc. (Formerly Known As PerkinElmer, Inc.) (U.S.)
  8.5.5. Agilent Technologies, Inc. (U.S.)

9. COMPANY PROFILES (BUSINESS OVERVIEW, FINANCIAL OVERVIEW, PRODUCT PORTFOLIO, STRATEGIC DEVELOPMENTS, AND SWOT ANALYSIS)

9.1. Thermo Fisher Scientific, Inc.
9.2. Illumina, Inc.
9.3. Merck KGaA
9.4. Revvity, Inc.
9.5. Agilent Technologies, Inc.
9.6. QIAGEN N.V.
9.7. Sino Biological, Inc.
9.8. Capitalbio Technology Co., Ltd.
9.9. Arrayit Corporation
9.10. Raybiotech Life, Inc.
(SWOT analysis is provided for top 5 players)
Table 1 China: Number of New Cancer Cases, by Type, 2022 Vs. 2045
Table 2 China: List of Personalized Medicine (PM)-related Policy Measures
Table 3 China: Major Genome Sequencing Projects
Table 4 China: Availability of Physicians and Nurses, 2022
Table 5 Microarray Instruments and Consumables: Average Selling Prices
Table 6 China Microarray Market, by Product, 2022-2031 (USD Million)
Table 7 China Microarray Consumables Market, by Type, 2022-2031 (USD Million)
Table 8 China Microarray Kits Market, by Type, 2022-2031 (USD Million)
Table 9 China DNA & RNA Microarray Kits Market, by Type, 2022-2031 (USD Million)
Table 10 China Microarray Market, by Application, 2022-2031 (USD Million)
Table 11 China Microarray Market, by End User, 2022-2031 (USD Million)
Table 12 Contract Research Organizations Operating in China
Table 13 Recent Developments, by Company, 2021–2024


More Publications